Written By
Share This Article
Most MedTech/Medical Device CFOs accept field supply chain costs as a fixed cost of doing business. They are not fixed. They are recoverable. There are five distinct financial levers, each tied to a metric your board already tracks, that each should be quantifiable in your organization before any field inventory platform decision is made.
The Margin That’s Already Yours
There is a number buried in your field operations right now. It doesn’t appear on a budget line. It doesn’t show up in your ERP. But it surfaces every year in your write-off totals, your DSO trends, and the working capital that Treasury can’t see, can’t optimize, and can’t deploy.
That number: 200 to 400 basis points of annual Gross Margin erosion, is the cumulative output of five identifiable, measurable sources of financial friction in your field supply chain. Trunk stock that isn’t reconciled. Surgical cases that aren’t billed on time. Inventory over-provisioned because no one knows what’s already in the field. Capital tied up in consignment sitting on a hospital shelf for weeks and months.
None of these are strategic problems. They are operational friction problems. And operational friction, at enterprise scale, is a financial problem.
The Margin Recovery Framework identifies five levers that recover that margin systematically, each anchored to a metric your board already tracks, each actionable before you commit to any technology decision.
The Five Levers
Each lever below is tied to a specific board-level financial metric and supported by outcomes from real enterprise MedTech engagements.
Lever 1: Margin Recovery
The most direct measure of field supply chain performance is Gross Margin — and it is where the damage shows up first. Every unreconciled inventory transfer, every unbilled surgical case, every overnight shipment triggered by poor field visibility compounds into a measurable annual tax on your margin. These are not outlier events. They are the steady-state output of manual field operations, and at enterprise scale they account for 200 to 400 basis points of Gross Margin erosion every year.
Digitizing the field supply chain, chain-of-custody from warehouse to OR, bill-only capture automated at the point of care, inventory reconciled in real time, systematically eliminates each source of that erosion. The margin is already yours. It is simply being consumed by friction that can be measured and removed.
Lever 2: Working Capital Liberation (DSI)
The target metric here is Days Sales of Inventory (DSI), and the opportunity sits in the capital your business is already carrying but cannot see. Medical device companies routinely deploy significant inventory across sales reps' vehicles, hospital storage rooms, and consignment shelves. That capital is physically in the field but functionally stranded. It is not generating a return, it is not visible to Treasury, not flowing through Free Cash Flow the way it should.
Complete, real-time visibility into the last mile of your supply chain enables a 15 to 20 percent reduction in safety stock levels without impacting surgical case support or sales volumes. When you can see exactly what is where and when it was last used, you stop over-provisioning out of uncertainty. Stranded inventory converts to Free Cash Flow, your DSI improves, and the balance sheet reflects the actual efficiency of the business. That is not an operational improvement only, it is a capital event, the kind that gets mentioned in earnings calls.
Lever 3: Revenue Cycle Acceleration (DSO)
Days Sales Outstanding (DSO) is the metric, and the gap between a surgical case closing and an invoice being generated is where it bleeds. Product usage records are incomplete or disputed. Paperwork sits in a rep's inbox. Days or weeks pass before finance has what it needs to generate an accurate invoice, and every one of those days inflates DSO, delays cash recognition, and creates dispute risk downstream.
When the bill-only process is automated at the point of care, case item usage gets captured digitally, the case documented in real time, the invoice workflow triggered before the rep leaves the building, that is how the gap closes. Invoices go out in hours, not weeks. Finance receives clean, auditable records. Fewer disputes, faster payment, cleaner revenue recognition. A 3-5 day DSO reduction is achievable, and at scale, cash conversion efficiency is a metric analysts watch closely.
Lever 4: Build vs. Buy: The Hidden Capital Decision
The financial metric that matters here is Time to Value, measured against OpEx consumed. The pattern is consistent across MedTech: an internal IT team proposes building a custom field inventory solution. The business case looks reasonable. The first 80 percent of functionality ships on schedule. Then the project stalls. It stalls at the the surgical case management logic, at the multi-party consignment reconciliation, at the rep-to-rep transfers with chain-of-custody requirements. The final 20% is domain-specific complexity that general IT teams have simply never encountered.
Years pass. Budgets expand. The organization is left with a half-built system, a sunk cost, and the original problem unsolved. The more significant cost is not the direct spend, it is the opportunity cost of engineers and project managers who were not working on your core product pipeline, your commercial strategy, or your competitive differentiation for three years. A purpose-built platform deploys in 6 to 8 months. The financial question for CFOs, IT Leaders, Sales Leaders and Ops Leaders is not: “build or buy?”; it is what the true EBITDA impact is of delaying the right decision to finally adopt a comprehensive platform by another year.
Lever 5: The EBITDA Audit
The first four levers describe where the margin is. The EBITDA Audit answers the question that actually moves a board: how much is it in our organization, specifically, and what does the 3-year Net Present Value look like against the investment?
The EBITDA Audit is a scoped financial diagnostic — not a product demo, not a benchmark exercise. We focus on a single high-volume business unit or region, measure the actual rates of expedited shipping, inventory write-offs, expired product, and billing errors, and build an NPV model on your operational data. The output is a CFO-facing executive brief with the financial problem quantified, the 3-year NPV, and a clear recommendation built to present to your board. Clients typically see a 5 to 10 times return modeled over the three-year horizon. If the numbers in your organization don't justify action, we will tell you that directly.
The Framework Changes the Conversation
Most conversations about field inventory management get framed as operational conversations. Better visibility. Faster reconciliation. Fewer manual steps. These are real benefits, but they are the wrong entry point for a CFO.
The right entry point is the financial model. When a CFO sees 200–400 basis points of recoverable Gross Margin, a 15–20% reduction in safety stock, a 3–5 day DSO improvement, and a 5–10× NPV — all quantified on their own operational data — the conversation shifts. It stops being a technology evaluation and starts being a capital allocation decision. That is the conversation that gets CFOs off the sidelines and into the deal.
The five levers are not theoretical. They have been validated across enterprise MedTech manufacturers, in real operational environments, with real data. The question is not whether the margin exists in your field supply chain. It does. The question is how long it takes you to go find it and perform the value creation that drives your business forward.
Find Out What These Levers Are Worth in Your Organization
The Margin Recovery Framework is the foundation. The FIM Value Assessment is how you apply it to your specific operations, your data, and your board.
Schedule your FIM Value Assessment and find out exactly what your field operations are costing you, and what they could be returning.
